Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sars-Cov-2 Vaccination and Practical Points in Psoriasis Patients: A Narrative Review Publisher Pubmed



Aryanian Z1, 2 ; Balighi K1, 3 ; Hatami P1 ; Goodarzi A4, 5 ; Mohandesi NA6 ; Afshar ZM7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Dermatology, Babol University of Medical Sciences, Babol, Iran
  3. 3. Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Dermatology, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Dermatology, Mayo Clinic, Rochester, MN, United States
  7. 7. Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

Source: Dermatologic Therapy Published:2022


Abstract

SARS-CoV2 vaccines were approved without long-term monitoring due to emergent situations. This has raised some issues about timing and protocol of receiving vaccines in specific situations including patients with chronic inflammatory disorders such as psoriasis. Here, we present different aspects of SARS-CoV-2 infection and vaccination in psoriasis patients and aim to provide solutions to overcome the potential challenges. In brief, the benefits of vaccination outweigh the potential risk; vaccine-triggered de novo or flares of psoriasis is uncommon. As such, all psoriasis patients, especially those receiving systemic treatments including anti tumor necrosis factor agents, are strongly recommended to get SARS-CoV-2 vaccines. It is recommended that new immunosuppressive/immunomodulatory therapies be initiated at least 1 week after the second SARS-CoV-2 vaccine dose, if possible. In addition, in severe and active forms of psoriasis, it is better to delay vaccination until stabilization of the disease. © 2022 Wiley Periodicals LLC.
Related Docs
View other Related Docs
1. Covid Vaccine Recommendations in Dermatologic Patients on Immunosuppressive Agents: Lessons Learned From Pandemic, Journal of Cosmetic Dermatology (2022)
2. The Relationship Between Psoriasis, Covid-19 Infection and Vaccination During Treatment of Patients, Advances in Experimental Medicine and Biology (2023)
3. Generalized Pustular Psoriasis Flare-Up After Both Doses of Bbibp-Corv Vaccination in a Patient Under Adalimumab Treatment: A Case Report, Case Reports in Dermatology (2023)
4. The Role of Sars-Cov-2 Infection and Its Vaccines in Various Types of Hair Loss, Dermatologic Therapy (2022)
5. The Effects of Methotrexate on the Immune Responses to the Covid-19 Vaccines in the Patients With Immune-Mediated Inflammatory Disease: A Systematic Review of Clinical Evidence, Transplant Immunology (2023)
6. A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed Covid-19 Vaccine-Related Dermatologic Manifestations, American Journal of Dermatopathology (2023)
7. Kaposi's Sarcoma in a Patient With Pemphigus Vulgaris Mimicking Exacerbation of Pemphigus, Cancer Reports (2023)
8. Acute Generalized Exanthematous Pustulosis Following Sars-Cov-2 Virus: Remdesivir As a Suspected Culprit, Case Reports in Medicine (2022)
Experts (# of related papers)
View all Related Experts
Zeinab Aryanian (21)
Kamran Balighi (17)
Other Related Docs
9. Cutaneous Manifestations Following Covid-19 Vaccination: A Report of 25 Cases, Dermatologic Therapy (2022)
10. Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris?, Dermatologic Therapy (2022)
11. Covid-19 Vaccination in Children As a Global Dilemma Through an Ethical Lens: A Retrospective Review, Health Science Reports (2023)
12. The Covid-19 Pandemic and Its Impact on Esthetic Dermatology, Journal of Cosmetic Dermatology (2022)
13. Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19?, Journal of Cosmetic Dermatology (2023)
14. Coexistence of Pemphigus Vulgaris and Lichen Planus Following Covid-19 Vaccination, Case Reports in Dermatological Medicine (2022)
15. Epidemiology, Clinical Presentation, and Management of Pemphigoid Nodularis: An Update From Iran, Dermatologic Therapy (2022)
16. Pustular Psoriasis Flare-Up in a Patient With Covid-19, Journal of Cosmetic Dermatology (2021)
17. Recent Developments in Sars-Cov-2 Vaccines: A Systematic Review of the Current Studies, Reviews in Medical Virology (2023)
18. Covid-19 Vaccines: What Dermatologists Should Know?, Dermatologic Therapy (2021)
19. A 10-Year Survey on Lichen Planus Pemphigoides in Iran: A Therapeutic Conundrum, Dermatologic Therapy (2022)
20. Covid-19 and Exacerbation of Dermatological Diseases: A Review of the Available Literature, Dermatologic Therapy (2021)
21. Covid Vaccination in Patients Under Treatment With Rituximab: A Presentation of Two Cases From Iran and a Review of the Current Knowledge With a Specific Focus on Pemphigus, Dermatologic Therapy (2022)
22. Two Asymptomatic Facial Erythematous Macules in an Adult Male, Skin Health and Disease (2023)
23. Rituximab As a Maintenance Treatment in Patients With Pemphigus Vulgaris: When Is the Right Time for Discontinuation?, Journal of Cosmetic Dermatology (2024)
24. Covid-19 Vaccines and Filler Reactions: Should It Be Considered As a Concern?, Journal of Cosmetic Dermatology (2022)
25. Serious Health Threat of Mucormycosis During the Ongoing Covid-19 Pandemic: What Dermatologists Need to Know in This Regard, International Journal of Dermatology (2022)
26. Multiple Cycles of Rituximab Therapy for Pemphigus: A Group of Patients With Difficult- To-Treat Disease or a Consequence of Late Rituximab Initiation?, Dermatologic Therapy (2022)
27. Prevalence and Management of Chronic Hepatitis B in Pemphigus and Pemphigoid Patients: New Evidence for the Safety of Rituximab, Dermatologic Therapy (2022)
28. Pustular Psoriasis Exacerbated by Covid-19 in a Patient With the History of Psoriasis, Dermatologic Therapy (2020)
29. Safety and Adverse Events Related to Covid-19 Mrna Vaccines; a Systematic Review, Archives of Academic Emergency Medicine (2022)
30. A Literature Review on Janus Kinase (Jak) Inhibitors for the Treatment of Immunobullous Disorders, International Immunopharmacology (2022)
31. Various Aspects of the Relationship Between Vitiligo and the Covid-19 Pandemic or Sars-Cov-2 Vaccines: Clinical Pearls for Dermatologists, Journal of Cosmetic Dermatology (2023)
32. Frequency of Skin Lesions in Healthcare Workers During the Covid-19 Pandemic: An Update From Iran, Iranian Journal of Dermatology (2023)